JP Morgan Chase
PDLI

JP Morgan Chase’s PDL BioPharma, Inc. PDLI Stock Holding History

JP Morgan Chase’s Portfolio PDLI Stock Details PDLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-129,906
Closed -$432K – 6202
2020
Q3 		$432K Buy
129,906
+3,395
+3% +$10.8K ﹤0.01% 4046
2020
Q2 		$368K Sell
126,511
-26,782
-17% -$84.7K ﹤0.01% 3979
2020
Q1 		$432K Buy
153,293
+26,023
+20% +$83.9K ﹤0.01% 3886
2019
Q4 		$413K Sell
127,270
-637,799
-83% -$1.85M ﹤0.01% 4331
2019
Q3 		$1.65M Buy
765,069
+632,294
+476% +$1.69M ﹤0.01% 3538
2019
Q2 		$405K Buy
132,775
+5,257
+4% +$17.1K ﹤0.01% 4333
2019
Q1 		$474K Sell
127,518
-81,665
-39% -$276K ﹤0.01% 4235
2018
Q4 		$606K Sell
209,183
-45,013
-18% -$124K ﹤0.01% 4031
2018
Q3 		$669K Buy
254,196
+115,956
+84% +$285K ﹤0.01% 4135
2018
Q2 		$323K Sell
138,240
-93,976
-40% -$262K ﹤0.01% 4364
2018
Q1 		$683K Sell
232,216
-349,364
-60% -$954K ﹤0.01% 3877
2017
Q4 		$1.59M Sell
581,580
-165,036
-22% -$507K ﹤0.01% 3447
2017
Q3 		$2.54M Sell
746,616
-477,042
-39% -$1.33M ﹤0.01% 3018
2017
Q2 		$3.02M Sell
1,223,658
-549,767
-31% -$1.26M ﹤0.01% 2803
2017
Q1 		$4.03M Buy
1,773,425
+236,745
+15% +$524K ﹤0.01% 2585
2016
Q4 		$3.26M Buy
1,536,680
+1,318,714
+605% +$3.68M ﹤0.01% 2760
2016
Q3 		$730K Sell
217,966
-22,973
-10% -$72.9K ﹤0.01% 3262
2016
Q2 		$757K Buy
240,939
+10,685
+5% +$35.6K ﹤0.01% 3281
2016
Q1 		$767K Buy
230,254
+11,747
+5% +$36.6K ﹤0.01% 3172
2015
Q4 		$774K Sell
218,507
-80,237
-27% -$336K ﹤0.01% 3226
2015
Q3 		$1.5M Sell
298,744
-2,717
-0.9% -$15.6K ﹤0.01% 2894
2015
Q2 		$1.94M Sell
301,461
-459,312
-60% -$3.08M ﹤0.01% 2930
2015
Q1 		$5.35M Sell
760,773
-490,586
-39% -$3.55M ﹤0.01% 2302
2014
Q4 		$9.65M Buy
1,251,359
+487,499
+64% +$3.86M ﹤0.01% 1979
2014
Q3 		$5.71M Buy
763,860
+464,655
+155% +$4.31M ﹤0.01% 2280
2014
Q2 		$2.9M Buy
299,205
+209,371
+233% +$1.87M ﹤0.01% 2351
2014
Q1 		$747K Sell
89,834
-811,436
-90% -$6.95M ﹤0.01% 2980
2013
Q4 		$7.61M Sell
901,270
-192,167
-18% -$1.62M ﹤0.01% 1919
2013
Q3 		$8.71M Buy
1,093,437
+46,544
+4% +$374K ﹤0.01% 1840
2013
Q2 		$8.08M Buy
+1,046,893
New +$8.16M ﹤0.01% 1814

Other funds holding PDLI

SPC
Silver Point Capital Greenwich, Connecticut $1.1B AUM 20.71% 1-Year Est. Return
PWAM
Park West Asset Management San Francisco, California $1.47B AUM 86.42% 1-Year Est. Return
GCIA
Gabelli & Co Investment Advisers Rye, New York $688M AUM 63.39% 1-Year Est. Return
JC
JBF Capital Aspen, Colorado $764M AUM 24.26% 1-Year Est. Return
GF
Gabelli Funds Rye, New York $15.7B AUM 36.4% 1-Year Est. Return
CCM
Context Capital Management Lajolla, California $5.15B AUM 1.28% 1-Year Est. Return
WG
Winton Group London, United Kingdom $3.09B AUM 40.4% 1-Year Est. Return
California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $177B AUM 39.86% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $114B AUM 41.71% 1-Year Est. Return
HW
Hancock Whitney Gulfport, Mississippi $6B AUM 34.57% 1-Year Est. Return

JP Morgan Chase's PDLI Position: Q4 2020 in Review

JP Morgan Chase sold out of PDL BioPharma, Inc. (PDLI) in Q4 2020, closing a stake of 129,906 shares — an estimated $432K sold.

JP Morgan Chase first reported a position in PDLI in Q2 2013 and held it in 30 quarters. The position peaked at $9.65M in Q4 2014. 33 funds tracked by Wall St. Rank hold PDLI as of Q4 2020.

  • JP Morgan Chase reported no remaining PDL BioPharma, Inc. position as of Q4 2020 after selling out during the quarter.
  • JP Morgan Chase sold 129,906 PDL BioPharma, Inc. shares in Q4 2020, an estimated $432K.
  • JP Morgan Chase first reported a position in PDL BioPharma, Inc. in Q2 2013 and held it in 30 quarters.
  • JP Morgan Chase's PDL BioPharma, Inc. position peaked at $9.65M in Q4 2014.
  • 33 funds tracked by Wall St. Rank held PDL BioPharma, Inc. as of Q4 2020.

Based on JP Morgan Chase's 13F filing for Q4 2020, filed 11 Feb 2021.